Gallus BioPharmaceuticals Receives Majority Investment from Ridgemont Equity Partners

Gallus BioPharmaceuticals, LLC, a St. Louis, MO-based premier biologics contract manufacturing organization, has received a majority investment from Ridgemont Equity Partners.

The investment, which was made by in partnership with the management of the company, facilitated Gallus’ acquisition of an existing FDA-approved, commercially-certified biologics manufacturing plant from Centocor Biologics, LLC. The proceeds will also be used to expand the facility’s manufacturing capabilities, including building a clinical services suite and expanding the existing development lab. The plant, which currently manufactures two of Centocor Biologics’ leading products, Remicade and Stelara, which are distributed globally, has capabilities for mammalian cell culture and protein purification in both perfusion and fed batch mode.

Gallus is led by President and CEO Mark Bamforth, with an experienced team of senior executives including Shelly Adams, Vice President of Sales and Marketing, Steven Kasok, CFO, and Mark Bell, Vice President of Site Operations.

In conjunction with the transaction, Jack Purcell and Walker Poole, a Principal and a Partner at Ridgemont respectively, will join Gallus’s Board of Directors.



Join the discussion